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Abstract
 
Vav1 is a signal transducing protein required for T cell receptor (TCR) signals that drive posi-
tive and negative selection in the thymus. Furthermore, Vav1-deficient thymocytes show
greatly reduced TCR-induced intracellular calcium flux. Using a novel genetic system which
allows the study of signaling in highly enriched populations of CD4
 

 
CD8
 

 
 double positive
thymocytes, we have studied the mechanism by which Vav1 regulates TCR-induced calcium
flux. We show that in Vav1-deficient double positive thymocytes, phosphorylation, and activa-
tion of phospholipase C-
 

 
1 (PLC
 

 
1) is defective. Furthermore, we demonstrate that Vav1 reg-
ulates PLC
 

 
1 phosphorylation by at least two distinct pathways. First, in the absence of Vav1
the Tec-family kinases Itk and Tec are no longer activated, most likely as a result of a defect in
phosphoinositide 3-kinase (PI3K) activation. Second, Vav1-deficient thymocytes show defec-
tive assembly of a signaling complex containing PLC
 

 
1 and the adaptor molecule Src homol-
ogy 2 domain–containing leukocyte phosphoprotein 76. We show that this latter function is
independent of PI3K.
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Introduction
 
Signals from the TCR play an important role in T cell de-
velopment in the thymus and in subsequent activation of T
cells in response to antigen. Biochemical analysis of TCR
signal transduction has shown that receptor stimulation leads
to the rapid activation of Src-family tyrosine kinases which
phosphorylate tyrosine residues within motifs named immu-
noreceptor tyrosine-based activation motifs that are found
 
on the 
 

 
 and CD3
 

 
, 
 

 
, and 
 

 
 subunits of the TCR complex
(1). Subsequently, the ZAP-70 tyrosine kinase binds to the
phosphorylated immunoreceptor tyrosine-based activation
motifs and is activated by further phosphorylation by Src-
family kinases. These activated kinases then rapidly phos-
phorylate multiple intracellular signal transducing proteins,
resulting in the generation of an intracellular calcium flux,
 
and activation of the ERK, c-Jun NH
 
2
 
-terminal kinase, and
p38 mitogen-activated protein kinase cascades. Ultimately
these signaling pathways converge on the nucleus causing
activation of a number of transcription factors and induction
of gene expression.
Vav1 is a 95-kD protein first isolated as an oncogene in a
3T3 fibroblast transformation assay (2). Subsequently, two
related proteins, Vav2 and Vav3, have been identified (3–
5). Vav1 was shown to be rapidly tyrosine phosphorylated
after stimulation of both the TCR and BCR (6–8). Analy-
sis of its sequence showed that it contained a number of
domains characteristic of signal transducing proteins (9, 10).
It has a Dbl homology domain common to GDP/GTP ex-
change factors (GEFs)
 
*
 
 for Rho-family GTPases. Vav1 it-
self was shown to be a specific GEF for Rac1, Rac2, and
RhoG, and to be activated by tyrosine phosphorylation
(11–13). In addition Vav1 contains an array of SH3-SH2-
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Abbreviations used in this paper:
 
 AB, air-buffered; DP, double positive;
 
GEF, GDP/GTP exchange factor; IP
 
3
 
, inositol 1,4,5-trisphosphate;
ITAM, immunoreceptor tyrosine-based activation motif; LAT, linker for
activation of T cell; PI3K, phosphoinositide 3-kinase; PIP
 
2
 
, phosphatidyl-
inositol 4,5-bisphosphate; PIP
 
3
 
, phosphatidylinositol 3,4,5-trisphosphate;
PIP5K, phosphatidylinositol 4-phosphate 5-kinase; PLC, phospholipase C;
SLP, Src homology 2 domain–containing leukocyte phosphoprotein.
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SH3 domains, suggestive of an adaptor-like function. Its
SH2 domain has been proposed to bind to a phosphoty-
rosine on the adaptor Src homology 2 domain–containing
leukocyte phosphoprotein (SLP)-76 which itself is part of
a complex including phospholipase C (PLC)
 

 
1 and the
adapters linker for activation of T cell (LAT) and Gads
which assembles after TCR stimulation (14–17).
The first indications of the importance of Vav1 in TCR
signaling came from studies in which we and others
showed that TCR-induced proliferation of T cells from
Vav1-deficient mice was greatly reduced, in part as a result
of decreased IL-2 production (18–20). Subsequently, it was
found that overexpression of Vav1 in Jurkat T cells led to
hyperactivation of TCR-induced activation of the tran-
scription factor nuclear factor (NF)-AT (21). Further analy-
sis showed that both positive and negative selection was
compromised in 
 
Vav1
 

 
/
 

 
 mice, consistent with Vav1
transducing TCR signals required for both of these selec-
tive events (22, 23). Biochemical studies demonstrated that
in 
 
Vav1
 

 
/
 

 
 CD4
 

 
 T cells, TCR-induced calcium flux,
ERK activation, and induction of the NF-
 

 
B transcription
factor were defective (24). In addition it has been shown
that 
 
Vav1
 

 
/
 

 
 T cells show reduced TCR capping, as well
as TCR clustering at the immunological synapse between a
T cell and an antigen-presenting cell (25–27).
In this study we address the mechanism by which Vav1
transduces TCR signals to the activation of an intracellular
calcium flux. Using a novel genetic system which allows
the study of signaling in highly enriched populations of
CD4
 

 
CD8
 

 
 double positive (DP) thymocytes, we show
that Vav1 regulates PLC
 

 
1 phosphorylation by at least two
distinct pathways. First, in the absence of Vav1 the Tec-
family kinases Itk and Tec are no longer activated, most
likely as a result of a defect in phosphoinositide 3-kinase
(PI3K) activation. Second, Vav1-deficient thymocytes
show defective assembly of a signaling complex containing
PLC
 

 
1 and the adaptor molecule SLP-76. We show that
this latter function is independent of PI3K.
 
Materials and Methods
 
Mice.
 
The generation of mice carrying a mutation disrupting
the 
 
Vav1
 
 gene (
 
Vav1
 
tm1Tyb/tm1Tyb
 
; 
 
Vav1
 

 
/
 

 
) and F5, 
 
Rag-1
 

 
/
 

 
,
 
	
 
2
 
m
 

 
/
 

 
 mice have been described previously (22, 28).
 
Stimulation of Thymocytes for Biochemical Analysis.
 
For all bio-
chemical analysis, thymi were disaggregated in air-buffered (AB)
IMDM. Cells were preincubated with the hamster anti–mouse
CD3
 

 
 mAb (10 
 


 
g/ml 2C11; BD PharMingen) on ice for 30
min, washed, and then incubated in AB IMDM for 5 min at
37
 

 
C before cross-linking of the antibodies with goat anti-Arme-
nian hamster IgG antiserum (75 
 


 
g/ml; Jackson Immunoresearch
Laboratories). Where PI3K inhibitors were used, thymocytes
were preincubated with 100 nM wortmannin (Sigma-Aldrich) or
10 
 


 
M Ly294002 (Sigma-Aldrich) at 37
 

 
C for 30 min before
standing on ice for 5 min. Preincubation with anti-CD3
 

 
 on ice
then proceeded as above, still in the presence of inhibitor. Subse-
quent cross-linking of 2C11 also occurred in the presence of in-
hibitor. For control samples where no inhibitor was used, an
equivalent volume of DMSO carrier was added.
 
Immunoblotting and Immunoprecipitation.
 
All chemicals were
obtained from Sigma-Aldrich unless otherwise indicated. Cells
were typically stimulated at 2 
 

 
 10
 
8
 
 cells per milliliter in AB
IMDM for the specified times and stimulation stopped by the ad-
dition of an equal volume of 2
 

 
 lysis buffer (2% n-octyl 
 
	
 
-D-
glucopyranoside, 50 mM Tris-Cl, pH 7.5, 5 mM EDTA, 150
mM NaCl, 20 mM NaF, 10 mM disodium pyrophosphate, 2
mM sodium orthovanadate, 1:50 [vol/vol] protease inhibitor
cocktail [P8340]; Sigma-Aldrich]). Cell lysates were cleared by
centrifugation at 15,340 
 
g
 
 for 15 min at 4
 

 
C and used for immu-
noprecipitations or if total cytoplasmic lysates were to be analyzed
directly, an equal volume of 2
 

 
 Laemmli sample buffer was
added before boiling for 3 min. Immunoprecipitations, immuno-
blotting, and SDS-PAGE were performed by standard proce-
dures. The following antibodies were used for immunoprecipita-
tion and immunoblotting: anti-PLC
 

 
1 rabbit polyclonal Ab (sc-
81; Santa Cruz Biotechnology, Inc.); anti-LAT rabbit polyclonal
Ab M41 (gift from M. Turner, Babraham Institute, Babraham,
UK); anti–SLP-76 sheep polyclonal Ab (gift from G. Koretzky,
University of Massachusetts, Worcester, MA); anti-Tec rabbit
polyclonal Ab (Upstate Biotechnology). Anti-Itk rabbit poly-
clonal Ab (USB) was used for immunoprecipitation. The follow-
ing antibodies were used for immunoblotting: anti-phosphoty-
rosine mAb RC20 conjugated directly to HRP (BD Transduction
Labs); anti-Itk mAb 2F12 (gift from L. Berg, University of Penn-
sylvania, Philadelphia, PA); anti-Gads rabbit polyclonal Ab (gift
from J. McGlade, Hospital for Sick Children, Toronto, Canada);
anti-phosphotyrosine783-PLC
 

 
1 (Biosource International); anti–
phosphothreonine308-Akt, anti–phosphoserine473-Akt, anti-Akt,
anti-phosphotyrosine319-ZAP-70, and anti-ZAP-70 rabbit poly-
clonal Ab (Cell Signaling Technology); and anti-Rac1 mAb
(USB). For immunoblots, antibody binding was revealed with
goat anti–mouse IgG-HRP (Santa Cruz Biotechnology, Inc.) for
mouse mAb, goat anti–rabbit IgG-HRP (Cell Signaling Technol-
ogy) or Protein A-HRP (Amersham Pharmacia Biotech) for rab-
bit polyclonal Ab, and donkey anti–sheep IgG-HRP (Serotec) for
sheep polyclonal Ab. For immunoprecipitations, immunocom-
plexes were isolated using protein A or protein G Plus agarose
(Santa Cruz Biotechnology, Inc.) for rabbit or sheep polyclonal
Ab, respectively.
For densitometric analysis the blots were scanned, bands of
interest were quantitated and in-lane background was sub-
tracted. To determine specific phosphorylation, the signal from
phosphorylated bands was divided by the signal from the appro-
priate loading control and all values were normalized to the
maximum response (set to 100%). Signals below detection were
set to 0%.
 
Rac1 Activation Assay.
 
For analysis of Rac1 activation, cells
were stimulated at 3 
 

 
 10
 
7
 
 cells per milliliter, lysed by the addi-
tion of an equal volume of 2
 

 
 pulldown buffer (2% Triton
X-100, 300 mM NaCl, 20 mM MgCl
 
2
 
, 2 mM sodium orthovan-
adate, 100 mM NaF, 2 mM PMSF, and 20 
 


 
g/ml leupeptin), and
cleared by centrifugation at 15,340 
 
g
 
 at 4
 

 
C for 2 min followed
by the addition of 0.03 vol of a slurry containing Glutathione-
Sepharose beads (Amersham Pharmacia Biotech) bound to bacte-
rially expressed GST-Pak1-RBD (fusion protein of GST with
amino acids 1–125 of rat Pak1, the Rac binding domain of Pak1).
Samples were rotated at 4
 

 
C for 5 min, washed twice in 1
 

 
 wash
buffer (0.1% Triton X-100, 50 mM Tris, pH 7.5, 500 mM NaCl,
10 mM MgCl
 
2
 
) before elution of Gst-Pak1-RBD-bound protein
using Laemmli sample buffer at 95
 

 
C.
 
Intracellular Calcium Analysis.
 
Intracellular calcium concentra-
tions were analyzed by flow cytometry using Indo-1 loaded thy-
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mocytes as described previously, except that the cells were only
stained with anti-CD3
 

 
 (22). CD3
 

 
 was cross-linked by the addi-
tion of goat anti–hamster IgG (75 
 


 
g/ml). Where required, cells
were preincubated with wortmannin or Ly294002 (concentra-
tions as above) at 37
 

 
C for 30 min before the addition of Indo-
1
 
AM
 
. Inhibitors were present throughout the anti-CD3
 

 
 prebind-
ing and cross-linking stages.
 
Inositol 1,4,5-Trisphosphate Measurement.
 
Thymocytes were stim-
ulated in AB IMDM (100
 
 

 
l) by cross-linking of CD3
 

 
 as de-
scribed above. The stimulations were terminated by the addition
of 15 
 


 
l ice-cold 6.1 M TCA followed by 15-min incubation on
ice. The samples were centrifuged at 1,400 
 
g
 
, 4
 

 
C for 15 min,
and the supernatant extracted with 10 vol water-saturated diethyl
ether, neutralized with 10 
 


 
l 1 M NaHCO
 
3
 
, and the final vol-
ume of the aqueous phase was adjusted to 200 
 


 
l with water.
Inositol 1,4,5-trisphosphate (IP
 
3
 
) was quantitated in duplicate or
triplicate 100 
 


 
l samples using a competitive [
 
3
 
H]IP
 
3
 
 binding as-
say (NEN Life Sciences) according to the manufacturer’s instruc-
tions.
 
Determination of Phosphatidylinositol 4,5-Bisphosphate Levels.
 
Pellets obtained after TCA-mediated cell lysis as above were
washed with 1 M TCA, 1 mM EDTA, and then water. The pel-
lets were extracted in methanol/chloroform/HCl (0.9 ml; 80:40:1),
for 15 min at room temperature with intermittent vortexing. To
this, chloroform (0.3 ml) and 0.1 M HCl (0.6 ml) was added and
0.4 ml of the lower phase was removed. After evaporation of sol-
vent under vacuum, 1 M KOH (0.25 ml) was added, and lipids
were hydrolyzed at 95
 

 
C for 15 min, which converts phosphati-
dylinositol 4,5-bisphosphate (PIP
 
2
 
) primarily to IP
 
3
 
. Hydrolyzed
extracts were passed through Dowex columns (0.4 ml) preequili-
brated with 5 ml 0.1 M HCl followed by 25 ml water. IP
 
3
 
 was
eluted from the column in 1.25 ml of water. Ether extraction fol-
lowed by neutralization with NaHCO
 
3
 
 and IP
 
3
 
 estimation was
performed as above. PIP
 
2
 
 levels were calculated from the IP
 
3
 
 val-
ues as described in the Biotrak IP
 
3
 
 assay kit (Amersham Pharma-
cia Biotech).
 
Results
 
A Genetic System Allowing the Study of the Biochemical Role
of Vav1 in DP Thymocytes.
 
In earlier studies, we and oth-
ers had shown that Vav1 was required for a normal TCR-
induced intracellular calcium flux in both thymocytes and
T cells (20, 22–26). Furthermore we showed that in CD4
 

 
T cells this was likely due to defective production of the
second messenger IP
 
3
 
 (24). We wished to pursue further
the biochemical pathway connecting Vav1 with the pro-
duction of IP
 
3
 
, however the relatively small number of T
cells that could be purified from Vav1/ mice was limit-
ing. Thus we switched to thymocytes, which provide a
much more abundant source of TCR-expressing cells.
Since Vav1/ mice have a greatly reduced ratio of single
positive to DP cells compared with Vav1/ mice (22, 23),
we used mice which were blocked in development so that
the only TCR-expressing cells are DP thymocytes poised
to receive a positive (or negative) selection signal (28). The
system consists of the F5 TCR transgene which expresses a
class I–restricted TCR specific for a peptide from influenza
nuclear protein presented by H-2Db on a background defi-
cient in recombinase activating gene (Rag)-1 (Rag-1/)
and MHC class I (	2m/). In the resultant F5, Rag-1/,
	2m/ mice, the absence of class I molecules causes a
complete block in positive selection and thus all the F5
TCR-expressing thymocytes are blocked at the DP stage.
To investigate the function of Vav1 within these cells we
bred the Vav1 mutation onto this background, generating
Vav1/, F5, Rag-1/, 	2m/ mice. As expected, thy-
mic development in these mice was also completely ar-
rested at the DP stage, which made up 90% of the thy-
mus, and the mutant and control cells were matched in
their expression of CD4, CD8, and TCR (Fig. 1 A).
Figure 1. Vav1 is required for normal TCR-driven calcium flux and
IP3 generation. (A) Dot plots showing flow cytometric analysis of CD4
and CD8 expression on thymocytes from F5, Rag-1/, 	2m/, and
Vav1/, F5, Rag-1/, 	2m/ mice (Vav1/ and Vav1/) showing
percentage of cells falling into a CD4CD8 DP gate. Histogram shows
levels of TCR-	 on DP thymocytes gated as on the dot plots. (B) Vav1/
or Vav1/ thymocytes were preloaded with Indo-1, coated with anti-
CD3, and the antibody cross-linked with goat anti–hamster antibody at
the time indicated by the break in the calcium trace and the short vertical
arrow. The graph shows the mean ratio of Indo-1 violet/blue fluores-
cence, a measure of intracellular [Ca2], as a function of time. (C) Graphs
showing mean levels of IP3 and PIP2 (SEM) in DP thymocytes stimu-
lated by cross-linking of CD3 as above. Results in this and all other fig-
ures are representative of at least three independent experiments.
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Vav1 Is Required for Normal TCR-driven Calcium Flux and
IP3 Generation in DP Thymocytes. Comparison of the F5,
Rag-1/, 	2m/ DP thymocytes with wild-type DP
cells showed that the peak TCR-induced calcium flux was
threefold higher in the monoclonal cells (data not shown).
This increase is mainly due to the lack of selecting MHC
(data not shown), presumably because in wild-type DP
thymocytes engagement of the TCR by peptide/MHC
desensitizes TCR signaling, a process which is absent in
the F5, Rag1/, 	2m/ thymus. Indeed such increased
TCR-induced calcium flux has been previously reported
in DP thymocytes and T cells in environments that were
MHC-deficient or expressed a limited repertoire of pep-
tide–MHC complexes (29, 30). Nonetheless we found
that the Vav1/ F5, Rag-1/, 	2m/ monoclonal DP
cells had a greatly decreased calcium flux compared with
F5, Rag-1/, 	2m/ cells (Fig. 1 B). This was similar to
the defect in calcium flux we and others previously re-
ported in Vav1-deficient thymocytes expressing a poly-
clonal TCR repertoire, thus validating the use of these
cells to study the biochemical role of Vav1 in TCR signal-
ing (19, 22, 23). In all further analysis we compared thy-
mocytes from F5, Rag-1/, 	2m/ and Vav1/, F5,
Rag-1/, 	2m/ mice (hereafter referred to as Vav1/
and Vav1/, respectively).
A key second messenger driving intracellular calcium
fluxes in lymphocytes is IP3, which is generated by the ac-
tion of PLC on PIP2. As shown in Fig. 1 C, the TCR-
driven production of IP3 is greatly diminished in Vav1/
DP thymocytes relative to Vav1/ cells, which likely ac-
counts for the large decrease in intracellular calcium flux.
This result is similar to the reduced TCR-induced IP3 gen-
eration that we previously demonstrated in Vav1/ CD4
T cells (24).
The defect in IP3 production could in principle be due
to a failure of PLC activation or localization, or to a short-
age of its substrate PIP2. It has been proposed that the
GTPase Rac1 may activate phosphatidylinositol 4-phosphate
5-kinase (PIP5K), the enzyme that generates PIP2 from its
precursor phosphatidylinositol 4-phosphate (31), and thus
Vav1, as a GEF for Rac1 could potentially regulate PIP5K
and thus the supply of PIP2. Indeed it has been shown that
in Vav1-deficient B cells, CD19-induced activation of
PIP5K is defective (32). To examine if a shortage of PIP2
might account for the defective IP3 production in Vav1/
thymocytes, we directly determined PIP2 levels in cells
stimulated through the TCR. Our results show that
Vav1/ cells had levels of PIP2, at least as high if not
higher than those seen in Vav1/ cells (Fig. 1 C). Thus it
seems unlikely that the defective TCR-induced IP3 gener-
ation is caused by a lack of substrate for PLC. However
since our analysis measures total cellular PIP2, we cannot
exclude that there is a small pool of PIP2 used by PLC in
which there is a selective shortage of the phospholipid.
Vav1 Is Required for Normal Tyrosine Phosphorylation of
PLC1. Generation of IP3 by signaling from antigen re-
ceptors is mediated by the PLC1 and 2 isoforms of the
enzyme whose activation is in part mediated by tyrosine
phosphorylation (33). Of these isoforms, PLC1 is likely to
be more important for TCR signaling, since, while PLC2
is required for normal antigen receptor signaling in B cells,
it appears to be dispensable for TCR signaling (34, 35).
Thus we analyzed TCR-induced tyrosine phosphorylation
of PLC1 in Vav1/ and Vav1/ DP thymocytes. Using
anti-phosphotyrosine Ab, we saw a clear reduction in
TCR-induced PLC1 phosphorylation in Vav1/ cells
(Fig. 2 A). Three distinct sites of phosphorylation have
been identified on PLC1: tyrosines 771, 783, and 1254
(36). Mutation of tyrosine 783 (Y783) to phenylalanine in
PLC1 blocked the phosphorylation-induced activation of
the enzyme, suggesting that this residue is critical for regu-
lation of PLC1 (36). Using antisera specific for phospho-
Y783 PLC1, we found that in Vav1/ DP thymocytes,
the TCR-induced phosphorylation of this residue is re-
duced, consistent with the defective activation of the lipase
(Fig. 2 A).
Vav1 Is Required for TCR-induced Phosphorylation of Tec-
family Kinases. Genetic experiments had shown that Lck,
ZAP-70, and Tec-family kinases as well as the LAT and
SLP-76 adapters were essential for normal TCR-induced
phosphorylation of PLC1 (1). Thus we examined each of
these molecules in turn, to identify a cause for the reduced
PLC1 phosphorylation. The TCR-induced activation of
Lck was assessed using an in vitro kinase assay and found to
be unaffected by the Vav1 mutation (data not shown), in
agreement with previous experiments in Vav1-deficient T
cells (24). Using an antiserum specific for phospho-Y319
of ZAP-70, a hallmark of its activation, we could see clear
induction of ZAP-70 phosphorylation in both Vav1/
and Vav1/ DP thymocytes (Fig. 2 B). Interestingly,
while the amount of pY319-ZAP-70 was similar between
Vav1/ and Vav1/ cells, mutant cells always showed a
higher specific phosphorylation of ZAP-70 due to lower
amounts of total ZAP-70 in the cells; the reason for this is
unclear. Immunoprecipitation of LAT or SLP-76 followed
by immunoblotting with anti-phosphotyrosine antibodies
showed inducible phosphorylation in Vav1/ cells which
was similar in magnitude to that observed in Vav1/ cells
(Fig. 2 B). Finally, we examined the phosphorylation of
Tec-family kinases. Three members of this family are ex-
pressed in the T lineage: Tec, Itk, and Rlk. Immunopre-
cipitation of Itk followed by immunoblotting with anti-
phosphotyrosine antibodies showed that its TCR-induced
phosphorylation in Vav1/ DP thymocytes was greatly
reduced compared with Vav1/ cells. Similarly, TCR
stimulation caused strong Tec phosphorylation in Vav1/
cells but only very weak phosphorylation in Vav1/ cells
(Fig. 2 C). We were unable to determine whether phos-
phorylation of the third Tec-family kinase Rlk was also
defective in Vav1/ cells due to the low sensitivity of
available anti-Rlk antibodies. Thus, in conclusion, we
have shown that Vav1 is required for TCR-induced phos-
phorylation and thus probably activation of Itk and Tec
kinases. In view of the demonstrated importance of Tec-
family kinases for PLC1 phosphorylation (37), it is likely
that the defect in PLC1 activation in Vav1/ cells can at
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least in part be explained by the defective Itk and Tec
phosphorylation.
Vav1 Regulates the Association of PLC1 with SLP-76.
While tyrosine phosphorylation is essential for the activa-
tion of PLC1, it is likely that the enzyme is regulated in
other ways as well. In particular it needs to be recruited to
the plasma membrane and to associate with a protein com-
plex containing the adaptor proteins linker for activation of
T cells (LAT), Gads, and SLP-76 (17). The transmembrane
adaptor protein LAT is phosphorylated on multiple ty-
rosine residues creating docking sites to which several other
proteins are recruited via SH2 domain–phosphotyrosine
interactions (38). These include the Gads adaptor molecule
which binds inducibly to LAT through its SH2 domain and
constitutively to the cytoplasmic adaptor SLP-76 via its
COOH-terminal SH3 domain (39, 40). PLC1 appears to
be recruited to this complex through at least two interac-
tions. It binds to phosphorylated LAT in a TCR stimula-
tion-dependent manner through its NH2-terminal SH2
domain and constitutively to SLP-76 via its SH3 domain
and both interactions are required for normal TCR-induced
phosphorylation (41, 42).
Since Vav1 is also thought to be recruited to this com-
plex (via SLP-76), we investigated whether its formation
might be defective in Vav1/ DP thymocytes. We immu-
noprecipitated LAT from Vav1/ and Vav1/ cells stim-
ulated through the TCR and immunoblotted the pre-
cipitates with anti-PLC1, anti-Gads, and anti–SLP-76
antibodies. Our results show that in DP thymocytes, TCR
stimulation induces the recruitment of all three of these
molecules to LAT, and that the extent of complex forma-
tion is similar in Vav1/ and Vav1/ cells (Fig. 3 A). We
examined the same associations in reverse by immunopre-
cipitating PLC1 or SLP-76 and analyzing the precipitates
Figure 2. Vav1 is required for normal tyrosine phos-
phorylation of PLC1 and Tec-family kinases. Vav1/ and
Vav1/ DP thymocytes were coated with anti-CD3 an-
tibody and then stimulated by cross-linking with a second-
ary antibody for the indicated times, or left unstimulated
(0 s). In some cases total cell lysates were analyzed directly
by immunoblotting with the indicated antibodies. In other
cases the protein of interest was immunoprecipitated with
specific antibody (IP Ab) and analyzed by immunoblotting
with blotting antibodies (Blot Ab). Equal loading was al-
ways evaluated by reprobing immunoblots with antibodies
specific for the protein being analyzed. Densitometry was
performed as in Materials and Methods, and all signals
were normalized to the maximum response (set to 100%).
(A) Phosphorylation of PLC1 on tyrosine 783 (pY783)
was analyzed by immunoblotting total cell lysates directly.
Total tyrosine phosphorylation on PLC1 (p-PLC1) was
analyzed by blotting PLC1 immunoprecipitates with
anti-phosphotyrosine (anti-pTyr) antibodies. (B) Phos-
phorylation of ZAP-70 on tyrosine 319 (pY319) was ana-
lyzed by immunoblotting total cell lysates directly. Tyro-
sine phosphorylation on LAT and SLP-76 was analyzed by
blotting immunoprecipitates with anti-pTyr antibodies.
(C) Tyrosine phosphorylation on Itk and Tec was analyzed
by blotting immunoprecipitates with anti-pTyr antibodies.
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for the presence of LAT. In both cases we were unable to
detect LAT itself, probably due to limitations of antibody
sensitivity, however using anti-phosphotyrosine antibodies
we could readily see the inducible association of a 36-kD
phosphoprotein (pp36) with both PLC1 and SLP-76,
which comigrated with LAT (data not shown). Our results
showed that the extent of TCR-induced association of
pp36/LAT with both PLC1 and SLP-76 was similar in
both Vav1/ and Vav1/ cells (data not shown).
Next we analyzed SLP-76 immunoprecipitates for the
presence of the Gads adaptor protein. As expected, we saw
a constitutive association of SLP-76 with Gads which did
not change after TCR stimulation, and was similar in
Vav1/ and Vav1/ cells (Fig. 3 B). Finally, we immu-
noprecipitated PLC1 and blotted the precipitates for the
presence of SLP-76. These experiments showed a weak
constitutive association between PLC1 and SLP-76 which
was strongly enhanced by TCR stimulation in Vav1/
cells (Fig. 3 C). In contrast, in Vav1/ cells, the constitu-
tive PLC1-SLP-76 association was reduced, and there was
very little further TCR-induced association. In view of the
demonstrated importance of the SLP-76-PLC1 associa-
tion for PLC1 phosphorylation, its large reduction in
Vav1/ DP thymocytes may well contribute to the ob-
served reduction in TCR-induced PLC1 activation.
Vav1 Is Required for TCR-induced PI3K Activation. The
phosphorylation and subsequent activation of Itk and Tec is
controlled at several levels. First, the kinases are recruited
to the plasma membrane. This is achieved by the binding
of phosphatidylinositol 3,4,5-trisphosphate (PIP3), pro-
duced by the action of PI3K on PIP2, to the PH domain of
Itk or Tec (43). Mutations in the PH domain that block
binding of PIP3, or treatment of cells with inhibitors of
PI3K inhibit the antigen receptor–induced activation of
both kinases (44, 45). Second, it has been proposed for Itk
that the inactive kinase exists in a self-inhibited state with
intramolecular interactions repressing activity (46). Binding
of ligands to various domains of Itk is proposed to promote
unfolding of these intramolecular interactions, eventually
leading to activation of the kinase after phosphorylation by
a Src-family kinase.
To investigate whether the defective phosphorylation of
Itk and Tec in Vav1-deficient cells might be due to a fail-
ure to activate PI3K, we analyzed the phosphorylation of
the serine/threonine kinase Akt as a surrogate for PI3K ac-
tivity. Akt is activated by at least three steps: membrane
recruitment driven by binding of phosphatidylinositol 3,4-
bisphosphate to the PH domain, phosphorylation on threo-
nine 308 (T308) by PDK1, a PIP3-activated kinase, and fi-
nally phosphorylation on serine 473 (S473) by a kinase
whose identity is unclear (47). Since phosphatidylinositol
3,4-bisphosphate is derived from PIP3 by the action of the
inositol phosphatase SHIP, the first two steps in the activa-
tion of Akt are dependent on PI3K. Analysis of TCR-
induced phosphorylation of Akt on T308 showed that it was
readily induced in Vav1/ DP thymocytes, but was unde-
tectable in Vav1/ cells (Fig. 4 A). Furthermore, analysis
of S473 phosphorylation showed that once again Vav1/
cells showed clear TCR-induced phospho-S473-Akt,
while Vav1/ cells were greatly diminished in this re-
sponse (Fig. 4 A). Taken together these results strongly
suggest that the TCR stimulation–induced activation of
PI3K was defective.
It has been suggested that Rac1 may activate PI3K (31,
48, 49). Since Vav1 is a GEF for Rac1 and Rac2 GTPases,
it is possible to construct a pathway from the TCR leading
to Vav1 phosphorylation, and then Rac1 and PI3K activa-
tion. To investigate this possibility further, we analyzed
TCR-induced Rac1 activation. As shown in Fig. 4 B, we
readily detected Rac1 activation after TCR stimulation in
Vav1/ cells; in contrast Vav1/ cells showed reduced
Rac1 activation. Thus, it is plausible that Vav1 regulates
PI3K through the activation of the Rac1 GTPase.
Vav1 Regulates PLC1 Activation via PI3K-dependent and
-independent Pathways. To investigate whether the role of
Vav1 in transducing TCR signals to the activation of
PLC1 was limited to the activation of PI3K, we com-
pared the effects of the Vav1 mutation with those of inhib-
itors of PI3K (Ly294002 and wortmannin). Treatment of
Vav1/ DP thymocytes with either inhibitor caused a
small decrease in the TCR-induced calcium flux relative to
untreated cells (Fig. 5 A, and data not shown). However
Figure 3. Vav1 regulates association of PLC1 and
SLP-76. Vav1/ and Vav1/ DP thymocytes were stim-
ulated and then analyzed by immunoprecipitation and
immunoblotting as described in Fig. 2. (A) Immunopre-
cipitates of LAT were analyzed for the presence of PLC1,
SLP-76, and Gads. (B) Immunoprecipitates of SLP-76
were analyzed for the presence of Gads. (C) Immunopre-
cipitates of PLC1 were analyzed for the presence of SLP-76.
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inhibitor-treated Vav1/ cells still showed a much larger
TCR-induced calcium flux than Vav1/ cells (Fig. 5 A).
To control for efficacy of the inhibitors we examined
TCR-induced Akt phosphorylation in Vav1/ or Vav1/
cells treated with Ly294002 or wortmannin. As ex-
pected, both inhibitors completely abolished TCR-
induced Akt phosphorylation on S473 (data not shown).
Taken together we conclude that in addition to regulating
Figure 4. Vav1 is required for TCR-induced Akt phosphorylation and
Rac1 activation. Vav1/ and Vav1/ DP thymocytes were stimulated
as described in Fig. 2. (A) Total cell lysates were analyzed for Akt phos-
phorylation by blotting with antibodies specific for phosphothreonine
308 (pT308) and phosphoserine 473 (pS473). (B) Rac1 activation was
evaluated by pulling down active GTP-loaded Rac1 with a GST fusion
protein containing the Rac binding domain of Pak1 (GST-Pak1-RBD)
and blotting with anti-Rac1 antiserum. Equal quantities of Rac1 in the
extracts were confirmed by immunoblotting a fraction of the total cell ly-
sates taken before the GST-Pak1-RBD pulldown.
Figure 5. Vav1 regulates PLC1 activation via PI3K-
dependent and -independent pathways. (A) Intracellular
calcium concentration in Vav1/ and Vav1/ DP thy-
mocytes stimulated by cross-linking CD3 was measured
by Indo-1 fluorescence as described in Fig. 1 B. Cells were
pretreated with the PI3K inhibitor Ly294002 as indicated.
Cells not treated with inhibitor were preincubated with
the appropriate concentration of the carrier DMSO. (B)
Tyrosine phosphorylation of PLC1 and association of
PLC1 with SLP-76 and Gads was determined using im-
munoprecipitates of PLC1 as described in Fig. 2 A and 3
C, respectively. Cells were pretreated with Ly294002 or
with the carrier DMSO as indicated.
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the activation of PI3K, Vav1 must also signal through a
PI3K-independent pathway leading to the activation of an
intracellular calcium flux.
To examine this in more detail, we analyzed the effects
of inhibiting PI3K on TCR-induced phosphorylation
of PLC1. Immunoblots with antibodies specific for
phosphoY783-PLC1 showed that treatment of Vav1/
cells with Ly294002 reproducibly decreased the TCR-
induced phosphorylation of this residue on PLC1 (Fig. 5
B). However, once again the inhibitor-treated Vav1/
cells showed a larger signal than Vav1/ cells. Immuno-
blotting PLC1 immunoprecipitates with anti-phosphoty-
rosine showed a similar picture; treatment of Vav1/ cells
with Ly294002 decreases TCR-induced phosphorylation
of PLC1, but not as much as disruption of the Vav1 gene
(Fig. 5 B). These experiments demonstrate that Vav1 likely
regulates the tyrosine phosphorylation of PLC1 by at
least two distinct pathways, only one of which is depen-
dent on PI3K.
Finally, we examined whether the defect in complex
formation between PLC1 and SLP-76 is dependent on
PI3K. Treatment of Vav1/ DP thymocytes with
Ly294002 caused no reproducible change in the TCR-
inducible association of PLC1 and SLP-76 (Fig. 5 B). In
contrast Vav1/ cells once again showed a decrease in
both the constitutive and inducible associations of these
molecules (Fig. 5 B). Reblotting of the same PLC1 im-
munoprecipitates for the Gads adaptor protein, showed
that its association with PLC1 mirrored that of SLP-76,
as would be expected given the constitutive SLP-76-
Gads association. Vav1/ cells showed TCR-inducible
association of PLC1 and Gads which was not affected
by Ly294002, whereas in Vav1/ cells, the basal and in-
ducible association was greatly decreased (Fig. 5 B).
These observations suggest that the PI3K-independent
pathway by which Vav1 transduces TCR signals to the
induction of PLC1 phosphorylation and hence intracel-
lular calcium flux may involve regulation of the associa-
tion of PLC1 with the SLP-76-Gads adaptor molecules
(Fig. 6).
Discussion
Using the F5, Rag-1/, 	2m/ system to analyze sig-
naling in DP thymocytes, we showed that in the absence of
Vav1, TCR-induced calcium flux, and IP3 production was
greatly reduced. This phenotype is similar to the one we
and others described for thymocytes and CD4 T cells ex-
pressing a polyclonal TCR repertoire, thus validating the
use of this system to study the biochemical role of Vav1
(20, 22–26).
We show here that after TCR stimulation, levels of PIP2
in Vav1/ DP cells remain as high if not higher than in
Vav1/ cells (Fig. 1 C), strongly suggesting that the defect
in IP3 production is due to a failure to activate PLC1
rather than a shortage of its substrate. In contrast, it has
been proposed that in Vav1/ B cells, the defective
CD19-induced calcium flux is due to a shortage of PIP2,
caused by defective activation of PIP5K (32). An earlier re-
port showed an interaction between Rac1 and PIP5K (31),
thus Vav1 could regulate this lipid kinase via its GEF activ-
ity toward Rac1. However, a more recent report questions
this, showing that PIP5K is regulated by the GTPase
ARF6, not Rac1 (50). How can we can reconcile our data
with the observed reduction in PIP5K activity in CD19-
stimulated Vav1/ B cells? One possibility is the differ-
ence in cell type and stimulus. Alternatively, we note that
rather than measuring PIP2 levels, this study measured the
synthesis of PIP2 after CD19 engagement and showed that
it is reduced in Vav1/ cells. If the levels of PIP2 are con-
trolled by negative feedback, as is common in many bio-
synthetic pathways, then a failure of PLC and PI3K acti-
vation would mean that PIP2 is not consumed and would
not need to be replenished, thus giving rise to the observed
decreased rates of PIP2 synthesis in Vav1/ cells.
PLC1 activity is regulated at several levels. It is re-
cruited to the plasma membrane through interactions with
membrane-associated protein complexes or via binding of
PIP3 to its PH domain and is phosphorylated on at least
three tyrosine residues (33, 51). Our data shows Vav1 regu-
lates TCR-induced PLC1 phosphorylation, and this is
likely to account for at least some of the defective PLC1
activity in Vav1/ DP cells. In contrast, we previously re-
ported that TCR-induced PLC1 phosphorylation was
normal in Vav1/ CD4 splenic T cells (24). This could
be due to a difference in signaling pathways used by the
TCR in T cells versus DP thymocytes. However, we note
that in our original studies we were hampered by the low
number of T cells we could purify and the insensitivity of
Figure 6. Cartoon of Vav-regulated pathways leading to PLC1 acti-
vation. TCR stimulation leads to the activation of the Lck and ZAP-70
kinases and the subsequent phosphorylation and activation of Vav. Vav
regulates the activation of PI3K (as readout by Akt phosphorylation)
possibly via Rac1, though there is no direct evidence for this. The
dashed arrow represents the requirement for PI3K in the activation of
Vav (54), leading to a potential positive feedback loop. Vav regulates
PLC1 activation by at least two pathways, one PI3K-dependent, most
likely through the activation of Itk and Tec. Secondly, Vav regulates the
association between PLC1 and the SLP-76 and Gads adapters indepen-
dently of PI3K activation. Rlk, another Tec-family kinase involved in
PLC1 phosphorylation is activated in a PI3K-independent fashion since
it does not have a PH domain (reference 61).
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the antibodies being used, which resulted in a very low sig-
nal to background ratio, making it difficult to see partial
decreases in PLC1 phosphorylation. In contrast, in the
current work, we have used a more sensitive anti-PLC1
Ab for immunoprecipitation and have had access to a much
larger number of cells from the DP thymocyte system, and
this may account for why we see a defect in PLC1 phos-
phorylation. Furthermore, the defect was also evident using
antiserum specific for phospho-Y783 of PLC1 (Fig. 2 A).
Mutational analysis has shown that phosphorylation of this
residue is critical for PLC1 activation (36), so its reduction
in Vav1/ DP thymocytes is likely to at least partially ac-
count for the failure to activate the enzyme. We note,
however, that the reduction in PLC1 phosphorylation is
less pronounced than that in TCR-induced IP3 produc-
tion. This may be because Vav1 does something other than
just regulate PLC1 phosphorylation; as we have shown,
Vav1 is required for normal PLC1/SLP-76 association.
Alternatively, the relationship between PLC1 phosphory-
lation and activity may be nonlinear, if for example several
tyrosines need to be phosphorylated to activate the lipase.
To understand the defect in TCR-induced PLC1
phosphorylation, we systematically studied most mole-
cules known from genetic studies to be required for this
event. While phosphorylation of ZAP-70 on Y319 and
total tyrosine phosphorylation of LAT and SLP-76 was
normal, the phosphorylation and hence probably activa-
tion of Itk and Tec kinases was defective. While mice de-
fective in a single Tec-family kinase show mild defects in
thymocyte development and TCR signaling, compound
mutations in Itk and Rlk cause a phenotype remarkably
similar to that in Vav1/ mice (37). As in Vav1 mutants,
Itk/, Rlk/ mice show defective positive selection, de-
creased TCR-driven T cell proliferation and IL-2 produc-
tion. Furthermore, biochemical analysis showed reduced
TCR-induced calcium flux, IP3 production, PLC1
phosphorylation, and ERK activation. Unfortunately, we
have been unable to determine if Rlk phosphorylation is
affected in Vav1/ cells, for lack of a sufficiently sensitive
antibody and the phenotype of the Itk/Tec double mutant
has not yet been reported, so we cannot compare it di-
rectly to the Vav1/ mice. However, extrapolating from
the phenotype of the Itk/, Rlk/ mice, it seems likely
that the reduced Itk and Tec activation will contribute
significantly to the observed PLC1 phosphorylation de-
fect. While the importance of Tec-family kinases for
phosphorylation and activation of PLC isoforms has been
demonstrated in a number of studies, the precise sites of
phosphorylation have not been determined. Our data sug-
gests that tyrosine 783 of PLC1 may be an important di-
rect target of Tec-family kinases.
The defective activation of PI3K in Vav1/ DP thy-
mocytes is the most likely cause for the failure to phos-
phorylate Itk and Tec. Both kinases contain a PH domain
through which they are recruited to the plasma membrane
after binding of PIP3, and this binding is a prerequisite for
phosphorylation and activation. However, we cannot ex-
clude that Vav1 may regulate these kinases by other mech-
anisms. Itk has been proposed to exist in an inhibited state
maintained by intramolecular interactions (46). Binding of
other proteins to domains of Itk involved in these internal
associations would open up the kinase allowing its activa-
tion by phosphorylation. Vav1 has been reported to bind
directly to Itk and Tec, and thus may contribute to their
activation by displacing these intramolecular associations
(52, 53).
The requirement for Vav1 in TCR-induced activation
of PI3K was unexpected, since it has been proposed that
PI3K is upstream of Vav1 (54). In these studies it was
shown that PIP3 binds to the PH domain of Vav1 and acti-
vates its GEF activity. Indeed a recent study has shown that
inhibition of PI3K leads to a reduction in TCR-induced
Vav phosphorylation (55). Taken together with our results
it seems that PI3K is both upstream and downstream of
Vav1, potentially creating a positive feedback loop (Fig. 6).
In agreement with our conclusions, recent work from
other groups has shown that Vav-family proteins may also
regulate antigen receptor-induced PI3K activation in mast
cells and B cells (56, 57).
It is unclear how Vav1 regulates PI3K. The effect may
be direct, in view of a report showing association of Vav1
with p85, a regulatory subunit of class 1 PI3K (58, 59). Al-
ternatively PI3K may be activated by the Rac1 GTPase,
since some reports have shown association between these
proteins (31, 48, 49). Interestingly, a genetic analysis of
PI3K and Rac1 activation in the Jurkat T cell line con-
cluded that in a pathway leading from TCR stimulation to
Akt activation, Rac1 was upstream of PI3K whereas in the
same cells, cytoskeletal rearrangements were induced by a
TCR signaling pathway in which PI3K was upstream of
Rac1 (60). Our results are consistent with the idea that in
thymocytes, the TCR signaling pathway leading to Akt
phosphorylation is mediated by Vav1 via Rac1 and then
PI3K activation.
It is most likely that PI3K contributes to PLC1 activa-
tion and TCR-induced calcium fluxes by regulating Tec-
family kinases as described above, however there are other
possibilities. PLC1 has been shown to bind PIP3 through
its PH domain and thus PI3K may regulate PLC1 activa-
tion directly (51). In addition, we have shown that Vav1
also contributes to PLC1 phosphorylation and activation
through a PI3K-independent pathway, by demonstrating
that the effects of the Vav1 mutation were more severe
than PI3K inhibitors (Fig. 5 A and B). Furthermore, we
identified a potential route for such a pathway by showing
that Vav1 regulates the association of PLC1 with the
adapters SLP-76 and Gads and that this association was
PI3K-independent (Fig. 5 B). This is likely to be significant
for the activation of the lipase as mutations in SLP-76
which block its ability to bind PLC1 lead to reduced
TCR-induced PLC1 phosphorylation (42).
The observation that in Vav1/ cells, the association of
LAT with PLC1, Gads, and SLP-76 was normal, whereas
that of PLC1 with Gads and SLP-76 was affected suggests
that there may be two distinct signaling complexes contain-
ing PLC1. Only one of these includes LAT, whereas the
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other, Vav1-dependent complex, apparently does not. An
interesting possibility is that this complex is nucleated
around a different adaptor protein which substitutes for
LAT. How Vav1 may regulate the assembly of such a com-
plex is unclear. Since Vav1 binds to SLP-76 after TCR
stimulation, it may stabilize the complex by directly bind-
ing to PLC1, or it might affect the ability of SLP-76 to
bind to PLC1 by an allosteric mechanism.
In conclusion, we have shown that in primary DP thy-
mocytes Vav1 transduces TCR signals to the phosphoryla-
tion and activation of PLC1 by at least two independent
pathways (Fig. 6). First, Vav1 transduces a signal which
leads to the activation of PI3K and phosphorylation of
Tec-family kinases, and second, independently of PI3K,
Vav1 regulates the formation of a signaling complex be-
tween PLC1 and the adaptor proteins Gads and SLP-76.
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